Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Karen M. Anderson, Chief People Officer at Centessa Pharmaceuticals plc (NASDAQ:CNTA), recently sold shares amounting to a total of $588,943. The transactions occurred on February 7 and February 10, 2025, with prices ranging from $18.99 to $19.0263 per share, near the company’s 52-week high of $19.09. The stock has shown remarkable strength, gaining over 105% in the past year. These sales were executed under a Rule 10b5-1 trading plan, which was adopted on September 13, 2024.
In addition to the sales, Anderson also acquired shares through option exercises on the same dates, totaling $124,129 at a price of $4.01 per share. Following these transactions, Anderson holds a total of 54,322 shares in the company.
The sales and acquisitions were part of routine trading activity and were disclosed in a Form 4 filing with the Securities and Exchange Commission. Track insider transactions and access comprehensive analysis with InvestingPro, which offers 14 additional investment tips for CNTA.
In other recent news, Centessa Pharmaceuticals announced the appointment of Stephen Kanes MD PhD as its new Chief Medical (TASE:PMCN) Officer, bolstering its leadership team as the company continues to advance its portfolio of orexin receptor 2 (OX2R) agonists. Dr. Kanes brings over 30 years of experience in neuroscience, clinical psychiatry, and drug development. The company’s lead OX2R agonist, ORX750, is currently in Phase 2 clinical trials, with multiple clinical milestones expected this year.
In line with these developments, Cowen research firm initiated coverage of Centessa Pharmaceuticals, assigning a Buy rating to the company, buoyed by the potential of the drug candidate ORX750. Cowen analysts expressed optimism about ORX750’s prospects, citing its "best in class profile" which could be transformative for patients suffering from hypersomnia indications.
Leerink Partners showed confidence in Centessa Pharmaceuticals by raising the stock’s price target to $24 from $22 while maintaining an Outperform rating. The firm’s updated model reflects a more optimistic view on Centessa’s product pipeline, particularly the ORX750 program. Leerink Partners increased its projections for Centessa’s total company sales in 2032 by 4% and earnings per share (EPS) by 18%.
Finally, Guggenheim maintained a positive outlook on Centessa Pharmaceuticals, raising the price target to $28 from the previous $24 while keeping a Buy rating on the stock. The firm’s analyst highlighted the recent strategic developments from the company, particularly the single ascending dose (SAD) and multiple ascending dose (MAD) updates for ORX750. The anticipated data from these trials is expected in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.